Cyient Limited - 532175 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement22-04-2023
Cyient Limited - 532175 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper AdvertisementCyient Limited - 532175 - Consolidated Audit Report For The Quarter And Year Ended 31 March 2023
Consolidated Audit Report for the quarter and year ended 31 March 2023Cyient Limited - 532175 - Related Party Transactions For The Half-Year Ended 31 March 2023
Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015Cyient Limited - 532175 - Related Party Transactions For The Half-Year Ended 31 March 2023
Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015Cyient Results Earnings Call for Q4FY23
Conference Call with Cyient Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.Cyient Limited - 532175 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press ReleaseQ4FY23 Quarterly Result Announced for Cyient Ltd.
IT Consulting & Software company Cyient announced Q4FY23 results: Financial highlights for Q4FY23: Group revenue at $213.0 million; growth of 39.1% cc YoY (35.9% in US$) and 6.6% cc QoQ (8.1% in US$). Group revenue at Rs 17,514 million; growth of 48.3% YoY and 8.2% QoQ. Consolidated services revenue at $176.2 million; growth of 38.4% cc YoY (35.0% in US$) and 3.2% cc QoQ (4.9% in US$). Core services revenue growth is 12.0% cc YoY and 2.6% cc QoQ. Normalised group EBITDA margin at 18.4%; up by 118 bps QoQ and 30 bps YoY. Normalised group EBIT margin at 14.2%; up by 136 bps QoQ and down by 21 bps YoY. Normalised consolidated services EBIT margin at 15.1%; up by 117 bps QoQ and down by 27 bps YoY. Normalised free cash flow generation for the quarter at Rs 2,614 million, a conversion of 81.8% on normalised EBITDA(conversion of 148.6% on normalised PAT) Normalised PAT at Rs 1,760 mn for the quarter; growth of 14.1% YoY and 8.1% QoQ. Financial highlights for FY23: Group revenue at $746.3 million; growth of 26.9% cc YoY (22.7% in US$). Group revenue at Rs 60,159 million; growth of 32.7% YoY. Consolidated services revenue at $632.4 million; growth of 30.2% cc YoY (25.6% in US$). Core services revenue growth is 12.1% cc YoY. Normalised group EBITDA margin at 17.0%; down by 110 bps YoY. Normalised group EBIT margin at 12.8%; down by 113bps YoY. Normalised consolidated services EBIT margin at 13.7%; down by 160 bps YoY. Normalised free cash flow generation for the year at Rs 5,467 million, a conversion of 50.8% on normalised EBITDA (conversion of 96.7% on normalised PAT). Normalised PAT at Rs 5,651 million for the year; growth of 8.2% YoY. Highest ever total dividend of Rs 26 per share. Commenting on the results, Krishna Bodanapu, Executive Vice-Chairman and Managing Director, said “Cyient witnessed positive Q4FY23 results, with the highest quarterly group revenue at $213.0 million, growth of 6.6% QoQ, and 39.1% YoY in constant currency. The services revenue was $176.2 million, a growth of 3.2% QoQ and 38.4% YoY in constant currency, driven by growth across the transportation, mobility and sustainability BUs. The normalized group EBIT margins, at 14.2%, is higher by 136 bps QoQ and lower by 21 bps YoY due to the amortisation costs of acquisitions. The normalised group EBITDA margin, at 18.4%, is higher by 118 bps QoQ and 30 bps YoY. We continue to witness strong momentum across the business, driven by key wins, robust order intake, and a strong pipeline. We won 5 large deals in core services with a strong total contract potential of $185.1 million this quarter. We also witnessed significant growth across key accounts, with revenue from the top 30 accounts growing at 16.0% YoY in constant currency terms. We have a strong order intake at $212.7 million in Q4 FY23, which has contributed to the highest ever group order intake". Result PDFCyient Limited - 532175 - Intimation Of Grant Of Stock Options
Intimation of Grant of Stock OptionsCyient Limited - 532175 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation